Drug
Iniparib clinical trials
Also written BSI-201 and SAR240550.
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2010 (7)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 7 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Carboplatin (5) · Gemcitabine (4) · Temozolomide (2) · Paclitaxel (2) · Topotecan (1) · Irinotecan (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses iniparib is read from its arms, and is right about nine times in ten.
Testing it · 17
- Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant GliomaCompletedPhase 1/2SanofiNCT00687765Written as bsi-201 plus temozolomide
- Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical TrialCompletedPhase 3SanofiNCT01593228Written as Iniparib (SAR240550/BSI-201)
- Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsCompletedPhase 2SanofiNCT01204125Written as Iniparib (SAR2405550 -BSI-201)
- A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid TumorsCompletedPhase 1SanofiNCT00422682Written as bsi-201 + topotecan
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedPhase 2SanofiNCT01033292Written as BSI-201
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian CancerCompletedPhase 2SanofiNCT01033123Written as BSI-201
- Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)CompletedPhase 3SanofiNCT01082549Written as gemcitabine/carboplatin plus Iniparib
- A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast CancerCompletedPhase 2SanofiNCT00813956Written as gemcitabine plus carboplatin plus BSI-201
- A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain MetastasisCompletedPhase 2SanofiNCT01173497Written as INIPARIB + irinotecan
- Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast CancerCompletedPhase 2SanofiNCT01045304Written as Iniparib
- Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2SanofiNCT00677079Written as Iniparib
- An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)CompletedPhase 1SanofiNCT01161836Written as Iniparib
- SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung CancerCompletedPhase 2SanofiNCT01086254Written as Iniparib
- A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerCompletedPhase 3SanofiNCT00938652Written as Iniparib
- Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid TumorsCompletedPhase 1SanofiNCT01213381Written as Iniparib (SAR240550 - BSI-201)
- A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast CancerCompletedPhase 2SanofiNCT00540358Written as iniparib
- Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine CarcinosarcomaCompletedPhase 2SanofiNCT00687687Written as BSI-201 (Iniparib)
Given in every arm · 2 — iniparib is usual care beside what is tested
- A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid TumorsCompletedPhase 1SanofiNCT01455532Written as Iniparib (SAR240550-BSI-201)
- Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid TumorsCompletedPhase 1SanofiNCT00298675Written as BSI-201 (iniparib)
Codes
What other systems call iniparib · ClinicalTrials.gg INT003817
- MeSH (NLM) C090712iniparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2ZWI7KHK8FINIPARIBConfirmed FDA, NLM, Wikidata
- Wikidata Q260286iniparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62526IniparibOne source FDA
- DrugBank DB13877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090712 | iniparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2ZWI7KHK8F | INIPARIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q260286 | iniparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62526 | Iniparib | One source FDA |
| DrugBank | DB13877 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.